Rep. Brad Knott's Recent Trade: Insights on Oramed Pharma

Author: Dylan Bailey Updated: 02-26-2025 10:03 AM

Rep. Brad Knott Reports Sale in Oramed Pharmaceuticals

Recently, Representative Brad Knott announced a sale of Oramed Pharmaceuticals stock, with the value of this transaction being reported between $15,001 and $50,000. This update sheds light on the dynamic nature of trading among congressional members and the impact it can have on investor perceptions.

Overview of the Transaction

The trade concerning Oramed Pharmaceuticals (ORMP) has sparked interest in the market, especially as shares currently sit at $2.15. Although the price remains unchanged, understanding the context of congressional trading is crucial for investors who closely monitor such activities.

The Relevance of Congressional Trades

Every time a congressional representative engages in trading, it is essential to take note. These transactions are mandatory for public disclosure, meant to ensure transparency and prevent any misuse of insider information. Congress members are required to file a Periodic Transaction Report within 30 days of being notified of their transaction and within 45 days of the actual trade.

Legislation Governing Trading Activities

In an effort to maintain ethical standards, the STOCK Act was signed into law in 2012, aimed at curbing potential abuses. This law prohibits members of Congress from using privileged information for personal gain concerning stock trades. It also enforces stricter requirements for transparency and public disclosure.

Investor Considerations

While congressional transactions should not solely dictate an investor's decision-making, they can offer hints about potential market movements. For instance, when a member like Representative Knott purchases stock, it might indicate anticipation of a price increase. Conversely, a sale can occur for various reasons and does not automatically suggest a decline in stock value.

Interpreting Congressional Trades

For astute investors, understanding the intricacies behind congressional trading could prove beneficial. Analyzing why representatives make certain trades might provide insights into market trends and opportunities. Ultimately, while these transactions warrant attention, they should complement a broader investment strategy rather than serve as the sole basis for decisions.

Frequently Asked Questions

What was the value of Rep. Knott's stock sale?

Rep. Knott's sale of Oramed Pharmaceuticals was valued between $15,001 and $50,000.

What is the current trading price of Oramed Pharmaceuticals?

Oramed Pharmaceuticals shares are currently trading at $2.15.

What is the STOCK Act?

The STOCK Act is legislation that prohibits Congress members from trading based on nonpublic information and requires them to disclose their trades.

Why should investors pay attention to congressional trades?

Congressional trades can provide insights into potential market movements and indicate how lawmakers view specific stocks.

How often are congress members required to report trades?

Congress members must report their trades within 30 days of being notified and no later than 45 days after the transaction date.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.